COVID-19 Vaccines: Systematic review
Rasiklal M. Dhariwal Institute of Pharmaceutical Education and Research; Chinchwad, Pune-411019, MH- India.
Review Article
World Journal of Advanced Research and Reviews, 2021, 10(01), 143–155
Article DOI: 10.30574/wjarr.2021.10.1.0118
Publication history:
Received on 20 February2021; revised on 01 April 2021; accepted on 03 April 2021
Abstract:
World facing pandemic challenges of SARS-Co-2 (Severe Acute Respiratory Syndrome Corona Virus 2). Tyrrell and Bynoe identified first strain of human corona virus in 1965. Infection was originated from Wuhan city of China on November 2019. Virus officially named as COVID-19 which causes respiratory tract infections in humans. Preliminary symptoms like chest pain with difficulty in breathing, reduced in systemic oxygen level, cough and fever. At present, the majority of the pharmaceutical companies were in race to developing antiviral drug and vaccines against COVID-19. Industries conducting the experiment and clinical trial of various vaccines to ensure effectiveness and safety on human. Several of them were documentation for patent, authorization of clinical trial and marketing. We provide an overview of Covid-19 history, types of vaccine and mechanism of actions, current future therapeutic drugs and patents. Relative with the mechanism of actions such as inactivated vaccine, vector vaccines, DNA and RNA based vaccine and antiviral drugs already entered in (Phase II and III) clinical trials.
The systemic study specified brief summary of various vaccines. Current status of clinical trial, safety and effectiveness according to ICH guidelines. A major adverse interaction with their toxicity study. The information of approved which give opportunity for upcoming scientist to improve the quality, and minimize the adverse effects. Scientist may face challenges during the post marketing clinical trial. This pandemic has provided various scopes for researchers to develop vaccine and antiviral drugs.
Keywords:
SARS COV-2; Covid – 19; vaccine; virus; Covaxin; Pfizer.
Full text article in PDF:
Copyright information:
Copyright © 2021 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0